{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T16:03:34Z","timestamp":1781021014161,"version":"3.54.1"},"reference-count":71,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,9]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Diffuse large B-cell lymphoma (DLBCL) exhibits marked heterogeneity, complicating treatment and prognosis. The role of plasma cell\u2013like phenotypes in DLBCL remains underexplored. Using spatially resolved transcriptomics, we profiled 4 distinct plasma cell\u2013like phenotypes in DLBCL based on CD20, HLA-DRA, and PR domain zinc finger protein 1 (PRDM1) markers: CD20+HLA-DRA+ PRDM1\u2212, CD20+ HLA-DRA+ PRDM1+, CD20+ HLA-DRA\u2212PRDM1\u2212, and CD20+ HLA-DRA\u2212PRDM1+. The CD20+ HLA-DRA+ PRDM1\u2212 phenotype (nonplasma cell\u2013like phenotype) had better prognosis; the other 3 phenotypes (plasma cell\u2013like phenotypes) had worse prognosis. Patients with &amp;gt;30% plasma cell\u2013like phenotype cells were classified as DLBCL plasma cell\u2013like phenotype predominant (DLBCLPCPP), and those with \u226430% as DLBCL plasma cell\u2013like phenotype deficient (DLBCLPCPD). Plasma cell\u2013like phenotype cells correlated with reduced proliferation, impaired immune function, and enhanced tumor microenvironment remodeling. DLBCLPCPP had lower Ki-67 index of \u226585% (29.6% vs 53.9%, P = .0198), similar first-line response (92.6% vs 92.6%, P = 1.00) but a higher rate of disease progression within 12 months (25.9% vs 3.7%, P = .0238) and more B2M alterations (22.2% vs 3.7%, P = .0509) compared with DLBCLPCPD. Transcriptomic revealed of plasma cell\u2013like phenotype cells to plasmablastic lymphoma. Using phenotype-associated genes, we constructed a random forest model to predict bortezomib response. High plasma cell\u2013like phenotype signatures were linked to poorer progression-free survival (PFS) but greater benefit from R-CHOP (rituximab, cyclophosphamide, doxorubicin, Oncovin [vincristine], and prednisone) plus bortezomib (RB-CHOP), low-signature patients achieved better PFS with R-CHOP alone. These findings characterize the transcriptomic features of distinct plasma cell\u2013like phenotypes in DLBCL, offering new insights for prognostic relevance and individualized treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018014","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T18:57:35Z","timestamp":1774551455000},"page":"3966-3982","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Digital spatial profiling uncovers transcriptomic features of distinct plasma cell\u2013like phenotypes in diffuse large B-cell lymphoma"],"prefix":"10.1182","volume":"10","author":[{"given":"Zucheng","family":"Xie","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Qin","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital and Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7842-6883","authenticated-orcid":false,"given":"Xuemin","family":"Xue","sequence":"additional","affiliation":[{"name":"3Department of Pathology, State Key Laboratory of Molecular Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinrui","family":"Chen","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongji","family":"Xie","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haohua","family":"Zhu","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liling","family":"Huang","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Yang","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianliang","family":"Yang","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Gui","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5192-3329","authenticated-orcid":false,"given":"Le","family":"Tang","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Feng","sequence":"additional","affiliation":[{"name":"3Department of Pathology, State Key Laboratory of Molecular Oncology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8450-7583","authenticated-orcid":false,"given":"Yuankai","family":"Shi","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Beijing Key Laboratory of Key Technologies for Early Clinical Trial Evaluation of Innovative Drugs for Major Diseases, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"issue":"4","key":"2026060911325765500_bib1","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jaci.2013.01.046","article-title":"B-cell biology and development","volume":"131","author":"Pieper","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2026060911325765500_bib2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1074-7613(02)00335-7","article-title":"Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program","volume":"17","author":"Shaffer","year":"2002","journal-title":"Immunity"},{"issue":"3","key":"2026060911325765500_bib3","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nri3814","article-title":"Germinal centres and B cell lymphomagenesis","volume":"15","author":"Basso","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"2026060911325765500_bib4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.2023022639","article-title":"Plasmablastic lymphoma: better refine prognosis","volume":"143","author":"Coppo","year":"2024","journal-title":"Blood"},{"issue":"15","key":"2026060911325765500_bib5","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1182\/blood-2014-10-567479","article-title":"The biology and treatment of plasmablastic lymphoma","volume":"125","author":"Castillo","year":"2015","journal-title":"Blood"},{"issue":"8","key":"2026060911325765500_bib6","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.3324\/haematol.2009.016113","article-title":"Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype","volume":"95","author":"Montes-Moreno","year":"2010","journal-title":"Haematologica"},{"issue":"6","key":"2026060911325765500_bib7","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1182\/blood-2011-07-363820","article-title":"Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma","volume":"119","author":"Wilkinson","year":"2012","journal-title":"Blood"},{"issue":"11","key":"2026060911325765500_bib8","doi-asserted-by":"crossref","first-page":"4251","DOI":"10.1182\/blood-2003-07-2365","article-title":"Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project","volume":"103","author":"Rimsza","year":"2004","journal-title":"Blood"},{"issue":"1","key":"2026060911325765500_bib9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2005-11-4742","article-title":"Loss of major histocompatibility class II gene and protein expression in primary mediastinal large B-cell lymphoma is highly coordinated and related to poor patient survival","volume":"108","author":"Roberts","year":"2006","journal-title":"Blood"},{"issue":"4","key":"2026060911325765500_bib10","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1158\/2159-8290.CD-18-1090","article-title":"Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition","volume":"9","author":"Ennishi","year":"2019","journal-title":"Cancer Discov"},{"issue":"3","key":"2026060911325765500_bib68","doi-asserted-by":"crossref","first-page":"110713","DOI":"10.1016\/j.celrep.2022.110713","article-title":"Pan-Hammarstr\u00f6m Q. A single-cell atlas of diffuse large B cell lymphoma","volume":"39","author":"Ye","year":"2022","journal-title":"Cell Rep"},{"issue":"1","key":"2026060911325765500_bib69","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41421-023-00559-7","article-title":"Single-cell landscape of primary central nervous system diffuse large B-cell lymphoma","volume":"9","author":"Liu","year":"2023","journal-title":"Cell Discov"},{"key":"2026060911325765500_bib70","doi-asserted-by":"crossref","first-page":"881345","DOI":"10.3389\/fgene.2022.881345","article-title":"Single-Cell RNA-Seq and Bulk RNA-Seq Reveal Intratumoral Heterogeneity and Tumor Microenvironment Characteristics in Diffuse Large B-Cell Lymphoma","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Genet"},{"issue":"10","key":"2026060911325765500_bib71","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.ccell.2021.08.011","article-title":"The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma","volume":"39","author":"Steen","year":"2021","journal-title":"Cancer Cell"},{"issue":"20","key":"2026060911325765500_bib15","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1182\/blood-2010-05-285320","article-title":"DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma","volume":"116","author":"Shaknovich","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2026060911325765500_bib16","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1038\/leu.2012.83","article-title":"Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study","volume":"26","author":"Visco","year":"2012","journal-title":"Leukemia"},{"issue":"9","key":"2026060911325765500_bib17","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1158\/1078-0432.CCR-16-1922","article-title":"Biological and clinical relevance of associated genomic alterations in MYD88 L265P and non-L265P-mutated diffuse large B-cell lymphoma: analysis of 361 cases","volume":"23","author":"Dubois","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2026060911325765500_bib18","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"issue":"3","key":"2026060911325765500_bib11","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1200\/JCO.18.01314","article-title":"Molecular high-grade B-cell lymphoma: defining a poor-risk group that requires different approaches to therapy","volume":"37","author":"Sha","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"2026060911325765500_bib12","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1111\/bjh.15619","article-title":"Cell-of-origin in diffuse large B-cell lymphoma: findings from the UK's Population-Based Haematological Malignancy Research Network","volume":"185","author":"Painter","year":"2019","journal-title":"Br J Haematol"},{"issue":"11","key":"2026060911325765500_bib13","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1038\/leu.2015.109","article-title":"Gene expression analysis of plasmablastic lymphoma identifies downregulation of B-cell receptor signaling and additional unique transcriptional programs","volume":"29","author":"Chapman","year":"2015","journal-title":"Leukemia"},{"issue":"1","key":"2026060911325765500_bib14","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"24","key":"2026060911325765500_bib19","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1002\/cncr.31646","article-title":"Double hit and double expressors in lymphoma: definition and treatment","volume":"124","author":"Riedell","year":"2018","journal-title":"Cancer"},{"issue":"7","key":"2026060911325765500_bib20","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"2026060911325765500_bib21","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41392-023-01358-y","article-title":"Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma","volume":"8","author":"Shen","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"2026060911325765500_bib22","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41587-020-0472-9","article-title":"Multiplex digital spatial profiling of proteins and RNA in fixed tissue","volume":"38","author":"Merritt","year":"2020","journal-title":"Nat Biotechnol"},{"issue":"7","key":"2026060911325765500_bib23","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2026060911325765500_bib24","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12859-017-1559-2","article-title":"Reactome pathway analysis: a high-performance in-memory approach","volume":"18","author":"Fabregat","year":"2017","journal-title":"BMC Bioinformatics"},{"issue":"3","key":"2026060911325765500_bib25","first-page":"100141","article-title":"clusterProfiler 4.0: a universal enrichment tool for interpreting omics data","volume":"2","author":"Wu","year":"2021","journal-title":"Innovation (Camb)"},{"issue":"1","key":"2026060911325765500_bib26","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/s13059-025-03784-3","article-title":"xCell 2.0: robust algorithm for cell type proportion estimation predicts response to immune checkpoint blockade","volume":"26","author":"Angel","year":"2025","journal-title":"Genome Biol"},{"key":"2026060911325765500_bib27","unstructured":"Ishwaran\n              H\n            , LauerM, BlackstoneE, LuM, KogalurU. randomForestSRC: Random Survival Forests Vignette. 2021. Accessed 19 November 2024. https:\/\/ishwaran.org\/vignettes\/survival.pdf."},{"issue":"1","key":"2026060911325765500_bib28","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","article-title":"Regression shrinkage and selection via the Lasso","volume":"58","author":"Tibshirani","year":"1996","journal-title":"J R Stat Soc Ser B (Methodological)"},{"issue":"4","key":"2026060911325765500_bib29","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S1074-7613(03)00267-X","article-title":"Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and pre-plasma memory B cells","volume":"19","author":"Shapiro-Shelef","year":"2003","journal-title":"Immunity"},{"issue":"8","key":"2026060911325765500_bib30","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1084\/jem.20040973","article-title":"Plasma cell ontogeny defined by quantitative changes in blimp-1 expression","volume":"200","author":"Kallies","year":"2004","journal-title":"J Exp Med"},{"issue":"5","key":"2026060911325765500_bib31","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.immuni.2007.04.007","article-title":"Initiation of plasma-cell differentiation is independent of the transcription factor Blimp-1","volume":"26","author":"Kallies","year":"2007","journal-title":"Immunity"},{"issue":"1","key":"2026060911325765500_bib32","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/modpathol.2016.162","article-title":"Plasmablastic lymphoma phenotype is determined by genetic alterations in MYC and PRDM1","volume":"30","author":"Montes-Moreno","year":"2017","journal-title":"Mod Pathol"},{"key":"2026060911325765500_bib33","doi-asserted-by":"crossref","first-page":"1354604","DOI":"10.3389\/fimmu.2024.1354604","article-title":"Plasmablastic lymphoma: current knowledge and future directions","volume":"15","author":"Li","year":"2024","journal-title":"Front Immunol"},{"issue":"2","key":"2026060911325765500_bib34","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1182\/blood.2023021348","article-title":"The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma","volume":"143","author":"Di Ciaccio","year":"2024","journal-title":"Blood"},{"issue":"8","key":"2026060911325765500_bib35","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/ajh.27376","article-title":"Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management","volume":"99","author":"Ramirez-Gamero","year":"2024","journal-title":"Am J Hematol"},{"issue":"21","key":"2026060911325765500_bib36","doi-asserted-by":"crossref","first-page":"2995","DOI":"10.1182\/blood.V124.21.2995.2995","article-title":"Plasmablastic lymphoma : a case series of the changing epidemiology of a rare extramedullary plasmacytoid neoplasm, diagnostic challenges, and therapeutic implications","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"issue":"5312","key":"2026060911325765500_bib37","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1126\/science.276.5312.596","article-title":"Repression of c-myc transcription by Blimp-1, an inducer of terminal B cell differentiation","volume":"276","author":"Lin","year":"1997","journal-title":"Science"},{"issue":"1","key":"2026060911325765500_bib38","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41571-021-00549-2","article-title":"The MYC oncogene - the grand orchestrator of cancer growth and immune evasion","volume":"19","author":"Dhanasekaran","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"2026060911325765500_bib39","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/leu.2016.243","article-title":"Loss of PRDM1\/BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma","volume":"31","author":"Xia","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"2026060911325765500_bib40","doi-asserted-by":"crossref","first-page":"616-628.e6","DOI":"10.1016\/j.immuni.2019.02.004","article-title":"A regulatory circuit controlling the dynamics of NF\u03baB cRel transitions B cells from proliferation to plasma cell differentiation","volume":"50","author":"Roy","year":"2019","journal-title":"Immunity"},{"issue":"7","key":"2026060911325765500_bib41","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/s12276-023-01013-0","article-title":"Cancer-associated fibroblasts: from basic science to anticancer therapy","volume":"55","author":"Yang","year":"2023","journal-title":"Exp Mol Med"},{"issue":"3","key":"2026060911325765500_bib42","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2026060911325765500_bib43","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s43018-021-00291-9","article-title":"A tumor-derived type III collagen-rich ECM niche regulates tumor cell dormancy","volume":"3","author":"Di Martino","year":"2022","journal-title":"Nat Cancer"},{"issue":"1","key":"2026060911325765500_bib44","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40164-025-00647-2","article-title":"Extracellular matrix stiffness: mechanisms in tumor progression and therapeutic potential in cancer","volume":"14","author":"Zhang","year":"2025","journal-title":"Exp Hematol Oncol"},{"issue":"8","key":"2026060911325765500_bib45","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1158\/2159-8290.CD-24-0002","article-title":"The interplay between extracellular matrix remodeling and cancer therapeutics","volume":"14","author":"Prakash","year":"2024","journal-title":"Cancer Discov"},{"issue":"7","key":"2026060911325765500_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2025.06.002","article-title":"Large B cell lymphoma microenvironment archetype profiles","volume":"43","author":"Li","year":"2025","journal-title":"Cancer Cell"},{"issue":"9759","key":"2026060911325765500_bib47","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"issue":"14","key":"2026060911325765500_bib48","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med Overseas Ed"},{"issue":"19","key":"2026060911325765500_bib49","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"issue":"7","key":"2026060911325765500_bib50","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3324\/haematol.2015.125344","article-title":"Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial","volume":"100","author":"Jaeger","year":"2015","journal-title":"Haematologica"},{"issue":"22","key":"2026060911325765500_bib51","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1200\/JCO.2017.72.6984","article-title":"Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"35","author":"Thieblemont","year":"2017","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026060911325765500_bib52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-136511","article-title":"Final analysis of the international double-blind randomized phase III study of lenalidomide maintenance in elderly patients with DLBCL in response after R-CHOP, the Remarc Study from Lysa","volume":"136","author":"Thieblemont","year":"2020","journal-title":"Blood"},{"issue":"4","key":"2026060911325765500_bib53","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med Overseas Ed"},{"issue":"17 suppl","key":"2026060911325765500_bib54","doi-asserted-by":"crossref","first-page":"LBA7003","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA7003","article-title":"Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: an interim analysis from the phase III DEB study","volume":"42","author":"Zhao","year":"2024","journal-title":"J Clin Oncol"},{"issue":"15","key":"2026060911325765500_bib55","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"2026060911325765500_bib56","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30935-5","article-title":"Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial","volume":"20","author":"Davies","year":"2019","journal-title":"Lancet Oncol"},{"issue":"15","key":"2026060911325765500_bib57","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1200\/JCO.23.00033","article-title":"Differential efficacy from the addition of bortezomib to R-CHOP in diffuse large B-cell lymphoma according to the molecular subgroup in the REMoDL-B study with a 5-year follow-up","volume":"41","author":"Davies","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16","key":"2026060911325765500_bib58","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1182\/blood.2019000241","article-title":"Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma","volume":"134","author":"Rosi\u00f1ol","year":"2019","journal-title":"Blood"},{"issue":"14","key":"2026060911325765500_bib59","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"2026060911325765500_bib60","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"2026060911325765500_bib61","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1038\/s41467-019-10812-x","article-title":"Human DEF6 deficiency underlies an immunodeficiency syndrome with systemic autoimmunity and aberrant CTLA-4 homeostasis","volume":"10","author":"Serwas","year":"2019","journal-title":"Nat Commun"},{"issue":"4","key":"2026060911325765500_bib62","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0198-8859(03)00024-7","article-title":"Molecular cloning of IBP, a SWAP-70 homologous GEF, which is highly expressed in the immune system","volume":"64","author":"Gupta","year":"2003","journal-title":"Hum Immunol"},{"issue":"3","key":"2026060911325765500_bib63","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1084\/jem.20111195","article-title":"Dual regulation of IRF4 function in T and B cells is required for the coordination of T-B cell interactions and the prevention of autoimmunity","volume":"209","author":"Biswas","year":"2012","journal-title":"J Exp Med"},{"issue":"10","key":"2026060911325765500_bib64","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1182\/blood.V89.10.3615","article-title":"Implication of a new molecule IK in CD34+ hematopoietic progenitor cell proliferation and differentiation","volume":"89","author":"Cao","year":"1997","journal-title":"Blood"},{"issue":"12","key":"2026060911325765500_bib65","first-page":"3449","article-title":"A new cytokine (IK) down-regulating HLA class II: monoclonal antibodies, cloning and chromosome localization","volume":"9","author":"Krief","year":"1994","journal-title":"Oncogene"},{"key":"2026060911325765500_bib66","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/2050-7771-1-11","article-title":"Nuclear protein IK undergoes dynamic subcellular translocation and forms unique nuclear bodies during the cell cycle","volume":"1","author":"Hu","year":"2013","journal-title":"Biomark Res"},{"issue":"1","key":"2026060911325765500_bib67","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.cytogfr.2014.09.003","article-title":"Negative regulation of RelA phosphorylation: emerging players and their roles in cancer","volume":"26","author":"Lu","year":"2015","journal-title":"Cytokine Growth Factor Rev"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/11\/3966\/2523794\/blooda_adv-2025-018014-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/11\/3966\/2523794\/blooda_adv-2025-018014-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:33:13Z","timestamp":1781019193000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/11\/3966\/567444\/Digital-spatial-profiling-uncovers-transcriptomic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":71,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,6,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018014","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6,9]]},"published":{"date-parts":[[2026,5,29]]}}}